LTRN vs LYEL

Lantern Pharma Inc. vs Lyell Immunopharma, Inc. — Valuation Comparison 2026

LTRN

Pharmaceutical Preparations
Lantern Pharma Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$3.59
Last close
Models
7/13
Active
VS

LYEL

Pharmaceutical Preparations
Lyell Immunopharma, Inc.
Quality
4.8
out of 10
Value Trap
32
LOW
Price
$17.33
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType LTRN Fair ValueLTRN Upside LYEL Fair ValueLYEL Upside
Bayesian DCF Intrinsic $1.04 -70.9% $4.45 -74.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.08 -96.1% $3.03 -85.4%
Dynamic NAV Asset-Based $1.28 -64.2% $14.95 -13.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for LTRN vs LYEL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LTRN vs LYEL — Which Stock Is More Undervalued?

LYEL scores higher with a 4.8/10 quality rating vs LTRN's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lantern Pharma Inc. (LTRN) and Lyell Immunopharma, Inc. (LYEL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LTRN currently trades at $3.59 with a QOC of 4.5/10, while LYEL trades at $17.33 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).